On March 23, 2026, Xilio Therapeutics, Inc. (Nasdaq: XLO) announced its financial results for the fourth quarter and full year ended December 31, 2025, alongside significant updates regarding its pipeline and business strategy. The company reported a cash position of $137.5 million, a substantial increase from $55.3 million at the end of 2024, bolstered by $35.8 million from Series B warrant exercises and a $17.5 million milestone payment from Gilead. Xilio's collaboration and license revenue surged to $13.7 million for Q4 2025, compared to $1.7 million in the same quarter of the previous year, reflecting the successful execution of its strategic partnerships.

Xilio is advancing its lead candidate, XTX501, a bispecific PD-1 / masked IL-2 therapy, with plans for an IND submission in mid-2026 and a Phase 1 trial initiation in the second half of 2026. The company is also progressing on a multi-specific masked T cell engager targeting PSMA and STEAP1, with a development candidate expected to be nominated in Q2 2026. These advancements are part of Xilio's strategy to leverage its proprietary masking technology to enhance the efficacy of immuno-oncology therapies while minimizing systemic side effects.

The company’s leadership expressed optimism about the future, with CEO Renée Russo highlighting the potential of their innovative therapies to address significant unmet needs in cancer treatment. Xilio plans to present new preclinical data at the upcoming AACR Annual Meeting, further showcasing its commitment to advancing its pipeline.

Overall, Xilio's financial results and strategic updates indicate a strong position for growth and innovation in the oncology space, with the potential for significant positive impact on its stock price as these developments unfold.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.